Probleme beim Einloggen
Ashwani Kailiya Peptide Based Cancer Therapeutics Market Expanding at an Impressive CAGR of 9.2% during the Forecast Period 2017-2022
Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug modification, stability, delivery and preclinical achievements is reflecting positively on the future prospects of the global peptide based cancer therapeutics market. Of late, an array of new peptides with encouraging preclinical results are undergoing clinical trials for treating cancer. At the same time, these new peptide are also finding application in various other therapeutic areas.
Forecast Highlights Of Global Market For Peptide Based Cancer Therapeutics
1- Among regions, North America is expected to remain the most attractive market for peptide based cancer therapeutics during the forecast period. This is largely due to the existence of several prominent peptide based cancer therapeutic drug makers and an advanced healthcare infrastructure in the region. Over the next couple of years, the region’s market is projected to witness a healthy growth. Meanwhile, the market in Asia-Pacific excluding Japan (APEJ) is anticipated to register the fastest CAGR over 2022.
2- Based on drugs, demand for bortezomib is expected to remain relative higher as compared to other peptide based cancer therapeutic drugs. Revenues from global sales of bortezomib drugs currently commands for nearly 40% market share. Towards the end of 2022, more than US$ 4,700 Mn worth bortezomib drugs are estimated to be sold worldwide.
3- Hospital pharmacies are the largest distribution channel for peptide based cancer therapeutic drugs followed by retail pharmacies. Currently, hospital pharmacies account for close to 50% share of the global market in terms of revenue. The trend is likely to continue in 2017 and beyond.
Peter Robb Cancer Pain Therapeutics Global Market 2016 - 2020, Research Report
About Cancer Pain Therapeutics
Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual’s body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.
Peter Robb Colorectal Cancer Therapeutics Market in APAC to Grow at a CAGR of 6.32% Over the Period 2015-2019
About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.


Infos zu den Moderatoren

Über die Gruppe "Onco'Zine - The International Cancer Network"

  • Gegründet: 17.01.2011
  • Mitglieder: 25
  • Sichtbarkeit: offen
  • Beiträge: 14
  • Kommentare: 0